Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Glycosciences and FDA to Study Proteomics of Toxicology

NEW YORK, Sept. 19-Oxford Glycosciences will work jointly with researchers at the U.S. Food and Drug Administration's drug evaluation center to identify serum protein biomarkers related to drug toxicity, the company said today.


The collaboration is a Cooperative Research and Development Agreement struck with the FDA Center for Drug Evaluation and Research.


FDA researchers will develop models of drug-induced toxic injury to heart, vascular and liver tissue and will generate biological samples from these experiments. OGS scientists will use the company's proteomics techniques to analyze these samples and identify serum markers specific to toxic response.


Under the terms of a CRADA, the FDA shares resources, personnel, expenses, and expertise with private industry partners, but does not provide direct funding.


For more information, see the press release.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.